TY - JOUR
T1 - Phenotypic differences between apolipoprotein e genetic subgroups
T2 - Research and clinical implications
AU - Caselli, Richard J.
N1 - Funding Information:
This work was supported in part by R01AG031581, P30AG19610, and the Arizona Alzheimer’s Consortium.
PY - 2012
Y1 - 2012
N2 - With the recent interest in Alzheimer's disease course modification and earlier, even preclinical, intervention, questions have arisen regarding the potentially confounding impact of apolipoprotein E (APOE) genotype on study design, therapeutic outcomes, and even clinical practice. APOE e4 carriers have a faster rate of cognitive decline both preclinically and during the mild cognitive impairment (MCI) stage, and a higher burden of cerebrovascular amyloid that may be the basis for the observed gene-dose-related increased frequency of immunomodulatory therapy-induced meningoencephalitis and cerebral microhemorrhages. To date, this has impacted study design in some research trials but not clinical practice.
AB - With the recent interest in Alzheimer's disease course modification and earlier, even preclinical, intervention, questions have arisen regarding the potentially confounding impact of apolipoprotein E (APOE) genotype on study design, therapeutic outcomes, and even clinical practice. APOE e4 carriers have a faster rate of cognitive decline both preclinically and during the mild cognitive impairment (MCI) stage, and a higher burden of cerebrovascular amyloid that may be the basis for the observed gene-dose-related increased frequency of immunomodulatory therapy-induced meningoencephalitis and cerebral microhemorrhages. To date, this has impacted study design in some research trials but not clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=84862280789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862280789&partnerID=8YFLogxK
U2 - 10.1186/alzrt123
DO - 10.1186/alzrt123
M3 - Review article
C2 - 22694803
AN - SCOPUS:84862280789
SN - 1758-9193
VL - 4
JO - Alzheimer's Research and Therapy
JF - Alzheimer's Research and Therapy
IS - 3
M1 - 20
ER -